Bedrocan Appoints Amy Stephenson As CFO

TORONTO, May 29, 2015 /CNW/ - Pursuant to the Company's announcement of May 5, 2015, Bedrocan Cannabis Corp. (TSXV: BED) ("Bedrocan" or the "Company") is pleased to announce the official appointment of Amy Stephenson as Chief Financial Officer, effective June 1, 2015.

Ms. Stephenson has more than 20 years senior management and capital markets experience.  Prior to joining Bedrocan, she spent 10 years in the CFO position for various public companies, including Ceres Global Ag Corp., Goldeye Explorations Ltd., Petroworth Resources Inc., and Augen Capital Corp. She has also worked as a business valuator at Evans & Evans, focusing on capital markets and M&A transactions. Her involvement as a principal and consultant M&A and project financing extends beyond North America to include Australia, China, Western Europe and Latin America.

Ms. Stephenson obtained her MBA in Finance from California State University, Sacramento, and her BA from the University of Hong Kong.  She is a CFA Charter holder, a Chartered Professional Accountant (CPA, CMA) and a member of the Financial Executive International (FEI).

As CFO, she succeeds Michael Singer, who served in that role for Bedrocan's first year of operation.

"We're very pleased to have attracted such a high caliber executive to join our team at this exciting time in our development," said Marc Wayne, President and CEO. "Amy brings valuable Canadian and international experience to Bedrocan, at a time when we are making the transition from an importer to a domestic producer.  We are executing successfully on Phase II of our strategic growth plan, with our domestic production facility now fully operational, increasing production capacity, and recent receipt of an expanded production license from Health Canada."

All officer appointments remain subject to TSX Venture Exchange approval.

About Bedrocan

Bedrocan and Bedrocan BV are focused on medicinal cannabis research and product innovation, and have been producing and supplying government-regulated medicinal cannabis for 13 years. Bedrocan's strains of pharmaceutical-grade cannabis have been used by more than 20,000 patients in seven countries, including Canada. The Company is committed to clinical research, with ISO 9001-rated production processes and product development, on an international scale. Bedrocan is one of only two companies currently supplying pharmaceutical-grade medicinal cannabis in Canada. Bedrocan Cannabis Corp. trades on the TSX Venture Exchange under the symbol "BED". www.bedrocan.ca

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Bedrocan Cannabis Corp.

Cam Battley, VP Communications and Corporate Development, Bedrocan Cannabis Corp., [email protected], +1.905.864.5525, www.bedrocan.ca